Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Damage-associated molecular patterns exacerbate atherosclerotic disease in CKD: Therapeutic suppression by the toll-like receptor inhibitor soluble TLR2

Cetin, Esra, Chaudhari, Asmita, Deshpande, Sumukh, Andrews, Robert, Meran, Soma ORCID: https://orcid.org/0000-0003-3408-3978, Ramji, Dipak Purshottam ORCID: https://orcid.org/0000-0002-6419-5578, Fraser, Donald ORCID: https://orcid.org/0000-0003-0102-9342, Labeta, Mario O. and Raby, Anne-Catherine ORCID: https://orcid.org/0000-0002-5354-5835 2026. Damage-associated molecular patterns exacerbate atherosclerotic disease in CKD: Therapeutic suppression by the toll-like receptor inhibitor soluble TLR2. Journal of the American Society of Nephrology 37 , 10S. 10.1681/ASN.2026vce9kg85

Full text not available from this repository.

Abstract

Background: Chronic kidney disease significantly increases the risk of cardiovascular mortality, with exacerbated atherosclerotic disease a major contributor to this risk. While CKD-associated chronic inflammation is believed to drive this association, the specific mechanisms are incompletely understood, and therapeutic options remain limited. Increased circulatory levels of Damage-Associated Molecular Patterns (DAMPs) - endogenous ligands for Toll-Like Receptors (TLR) – have been found in CKD, and we hypothesise that they contribute to worsening atherosclerotic disease in this population. Methods: Repurposed human proteomics data and LDLR-/- mice with Aristolochic Acid chronic nephropathy (AAN) were used to investigate the involvement of the DAMP:TLR pathway in worsening atherosclerosis in CKD and assess the efficacy of DAMP:TLR-targeting strategies to reduce this effect. Results: Repurposing of previously published proteomics data from a cohort of 66 patients with stage 3/4 CKD showed that several DAMPs were elevated in those who subsequently experienced a cardiovascular event. In mice, chronic nephropathy led to higher plasma DAMP levels and replicated key CV features observed in CKD, including: i) elevated plasma inflammatory cytokines, ii) increased circulating inflammatory monocyte proportions; iii) bigger atherosclerotic lesions that were iv) more inflammatory and more unstable. Single-cell transcriptomic analysis of aortas also revealed an enrichment in TLR-associated pathways in most cell populations identified. Critically, these effects were mediated by AAN-induced DAMPs, as treatment with soluble TLR2 (sTLR2), a multiple TLR inhibitor, counteracted the effects of AAN without reducing kidney disease or affecting lipid profiles. Notably, the Calprotectin inhibitor Paquinimod did not ameliorate atherosclerotic disease, suggesting the contribution of several DAMPs to the pathology. Conclusion: This study reveals the role of the DAMP:TLR signaling axis in worsening atherosclerotic disease in CKD and demonstrates the efficacy of a TLR inhibitory strategy to suppress this effect. Thus, it provides the foundation for future clinical studies aimed at evaluating sTLR2 as a therapeutic agent to improve cardiovascular outcomes in this challenging patient population.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Schools > Medicine
Schools > Biosciences
Publisher: American Society of Nephrology
ISSN: 1046-6673
Last Modified: 16 Nov 2026 13:00
URI: https://orca.cardiff.ac.uk/id/eprint/190953

Actions (repository staff only)

Edit Item Edit Item